Cowen Health Care Conference

Transcription

1 Cowen Health Care Conference Dr. Fouad Namouni Head of Medical March 7,

2 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. 2 2

3 Our R&D Strategic Focus DISEASE AREA FOCUS Oncology Cardiovascular Genetically Defined Diseases Immunoscience RA, IBD, Lupus Heart Failure Thrombosis Fibrotic Diseases Lung Liver Monogenic diseases 3

4 BMS Development Strategy High Disease High Severity Severity Potentially Large Treatment Enduring Unmet Need Effect Potentially Transformational Enduring Treatment Unmet Need Effect 4

5 2015: Leading in Immuno-Oncology 3 7 Early Trial Stops FDA Approvals 43 Global Approvals 7 NEJM Articles 5

6 Diversifying in Immuno-Oncology Next wave of innovation: addressing unmet need Improve outcomes through combinations Patients who do not respond to Opdivo +/- Yervoy Patients who progress after treatment with Opdivo +/- Yervoy Additional tumors, including where signals are not sufficient 6

7 2016: Diversifying in Immuno-Oncology Next wave of innovation: areas of focus Priming & Activation T Cell Trafficking and Infiltration T Cell Activation Antigen Presentation Antigen Release Tumor Microenvironment anti-csf1r anti-cd73 IDO BMS assets beginning clinical studies in Additional I-O Assets in Clinical Development NK cell T cell anti-lag3 Urelumab (anti-cd137) anti-gitr anti-ox40 NK Cell Activation Lirilumab (anti-kir) 7

8 Medical Insights LUNG Only PD-1 indicated for all 2 nd line NSCLC patients in US, EU*, and JP No testing requirement MELANOMA Strong access and reimbursement Broad range of treatment options First I-O combination regimen approved RENAL First I-O agent in 2 nd line in US and EU* Meaningful improvement over a standard of care * Non-squamous NSCLC and RCC indications are the subject of positive CHMP opinions in the EU and are awaiting EU Commission approval. 8

9 Strong Access Position Global Recognition of Value Unprecedented Speed Opdivo Select EU Products Months to patient access post approval Able to treat a broad number of patients 9

10 2016: Key Events Potentially Registrational Data Tumor 1L NSCLC CheckMate -026 Hodgkin Lymphoma CheckMate -205 Head and Neck CheckMate -141 Bladder CheckMate -275 Glioblastoma CheckMate -143 Non-Hodgkin Lymphoma CheckMate -139 Study Design Monotherapy vs. chemo in first-line PD-L1 expressers Monotherapy single arm study in second line Monotherapy vs. standard of care in second line (Study stopped for survival advantage) Monotherapy single arm study in second line bladder Monotherapy vs. standard of care in recurrent glioblastoma Monotherapy single-arm study in relapsed/refractory diffuse large B-cell lymphoma 10

11 Scientific Data Generation Region US Ex-US BMS Sponsored 7 5 ISR Other Includes Opdivo and Yervoy studies. 11

12 Checkmate-153: Advancing the Science in 2L NSCLC Advanced NSCLC (NSQ and SQ) At least 1 prior systemic therapy ~1,400 Patients Nivo 3 mg Q2 wkly Patient Subgroups: PS status Number of prior therapies Treated CNS Mets At 1 Year COHORT A Treat to progression, unacceptable toxicity, or withdrawal COHORT B Discontinue treatment at 1 year, allow re-treatment Primary Endpoint: Safety 12

13 Checkmate-370: Advancing the Science in 1L NSCLC Opdivo as maintenance Non-Squam EGFR wt, ALK wt Mono or combo with chemo vs chemo Non-small Cell Lung Cancer (NSCLC) Local Advanced or Stage IV, NSQ and SQ ~2,000 Patients Squam Non-Squam & Squam First Line EGFR wt, ALK wt First Line EGFR mut Mono vs best supportive care Opdivo as first-line treatment Mono vs. Chemo Combo with erlotinib vs erlotinib First Line ALK mut Combo with crizotinib 13

14 Leading Through Partnerships Master Trial Agreements with Key Centers Rare Population Malignancies Research Programs with Leading Academic Institutions International Immuno- Oncology Network Earle A. Chiles Research Institute University of Chicago Johns Hopkins University Royal Marsden Memorial Sloan-Kettering Cancer Center University College London Dana Farber Cancer Institute University Gustave Roussy NCI Naples University of Navarra Netherlands Cancer Institute WTZ Essen NCC Japan 14

15 Working Together for Patients 15

16 Cowen Health Care Conference Dr. Fouad Namouni Head of Medical March 7,